What to watch with CYP2D6 and blood sugar?

CYP2D6 is a key drug-metabolizing enzyme, responsible for breaking down many medications including beta-blockers, antidepressants, and opioids. There is no strong direct evidence linking CYP2D6 variants to blood sugar regulation. However, some drugs metabolized by CYP2D6 can affect glucose: beta-blockers may mask hypoglycemia symptoms, and certain antidepressants (e.g., paroxetine) are associated with increased diabetes risk. Weak GWAS signals have suggested possible associations between CYP2D6 polymorphisms and fasting glucose, but effect sizes are small and not clinically actionable. Consumer DNA tests for CYP2D6 are primarily useful for pharmacogenetic guidance, not for diabetes risk assessment. If you have a variant, discuss medication choices with a doctor. Evidence: unclear/mixed. Caveat: Do not use genetic results to diagnose or manage blood sugar without medical supervision.